Figure 2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026 Open access

Read full text
Authors: Evan Rosenbaum P. E, Rodrigo Gularte‐Mérida, Evan Seffar, Jasme Lee, Mathew Adamow, Martina Bradić, Mark Andrew Dickson, Viswatej Avutu, Lauren Baker Banks, Jason Earl Chan, Ping Chi, Mrinal M. Gounder
+18 more Ciara Marie Kelly, Mary Louise Keohan, Robert G. Maki, Sujana Movva, Damon R. Reed, Rhoena Desir, Matthew D. Biniakewitz, Joseph Patrick Erinjeri, Robert A. Lefkowitz, Phillip Wong, Cristina R. Antonescu, Li‐Xuan Qin, Katherine S. Panageas, Ronglai Shen, Samuel Singer, Andrew Koff, William D. Tap, Sandra P. D’Angelo
DOI: 10.1158/2767-9764.31429955
Cited by: 0

Abstract

Overview of scRNA-seq data. A, Cell clustering by UMAP. B, Expression of key markers within major cell populations, pooled among all specimens. C, Cell type proportion in each patient. Patients with paired biopsies were merged. D, Comparison of cell type proportions before vs. after retifanlimab initiation (IO) in patients with paired biopsies. UMAP, Uniform Manifold Approximation and Projection.

Fields of Study & Subjects

Sarcoma Diagnosis and Treatment Cancer Immunotherapy and Biomarkers Lymphoma Diagnosis and Treatment

Publication details

Publication date
27 February 2026
Language
EN